Signed in as:
filler@godaddy.com
PRAGMATIC PARTNERS HELPING YOU STEWARD THE COMPLEX JOURNEY
Amid constant change and rising complexity, clarity isn’t optional—it’s a competitive edge. ElevEx BioGroup partners with leaders to align strategy with vision and turn uncertainty into opportunity. Let’s talk.
SMART TEAMS DON'T PREDICT THE FUTURE - THEY PREPARE FOR IT.
Most Favored Nation (MFN) Impact Analysis & Launch Planning
Most Favored Nation (MFN) pricing has re-emerged as a strategic flashpoint in 2025, following renewed policy discussions tracing back to the Trump-era executive efforts and recent CMS and legislative activity.
As the US considers international reference pricing, companies must now explore how early ex-US decisions—launch, licensing, pricing—could shape long-term US revenue. While no one can predict exactly how policy will unfold, smart teams can prepare for multiple futures.
ElevEx BioGroup helps clients navigate these uncertainties through structured scenario planning, pricing simulations, and go/no-go analysis for key global markets. We also guide BD&L teams on how to license ex-US rights while preserving asset value.
When future policy paths are unclear, we help teams explore possibilities—pressure-testing strategies to protect pricing, access, and commercial outcomes under a range of real-world scenarios.
Pricing & Access Assessments: Commercial Reality Checks for Early-Stage Strategy
In the race to advance development programs, early-stage and emerging biotechs often underestimate the complexity of real-world Market Access—misjudging payer behavior, patient access hurdles, and the gross-to-net (GTN) implications of support programs, distribution, and competitive dynamics.
At Elevex BioGroup, we help clients pressure-test pricing assumptions and access expectations through strategic assessments that blend qualitative insight with directional, scenario-based analysis. Our work helps shape more grounded revenue forecasts by identifying critical market levers—payer tiering, hub service needs, specialty channel challenges, and value-based access requirements.
These insights don’t replace your forecast model—they strengthen it. By clarifying where risk resides, what will be required to secure meaningful access, and how real-world barriers may affect uptake, we help teams craft more realistic commercialization plans, represent value more credibly to partners or acquirers, and engage investors with greater confidence.
Forecasts are only as good as the assumptions beneath them. We help ensure those assumptions reflect access realities—not just clinical aspirations.